Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy

Pharmaceutics

Tianqi Wang¹  Jordan Dean¹  Jie Shen¹  Nikos Tapinos²  Yusuke Suita²  Saradha Miriyala² 

[1] Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA;Laboratory of Cancer Epigenetics and Plasticity, Brown University, Rhode Island Hospital, Providence, RI 02903, USA;

关键词: chemoimmunotherapy;    lipid-based nanoparticles;    liposomes;    cancer therapy;    immunotherapy;   

DOI  :  10.3390/pharmaceutics13040520

来源: DOAJ

【 摘 要 】

Nanomedicines have shown great potential in cancer therapy; in particular, the combination of chemotherapy and immunotherapy (namely chemoimmunotherapy) that is revolutionizing cancer treatment. Currently, most nanomedicines for chemoimmunotherapy are still in preclinical and clinical trials. Lipid-based nanoparticles, the most widely used nanomedicine platform in cancer therapy, is a promising delivery platform for chemoimmunotherapy. In this review, we introduce the commonly used immunotherapy agents and discuss the opportunities for chemoimmunotherapy mediated by lipid-based nanoparticles. We summarize the clinical trials involving lipid-based nanoparticles for chemoimmunotherapy. We also highlight different chemoimmunotherapy strategies based on lipid-based nanoparticles such as liposomes, nanodiscs, and lipid-based hybrid nanoparticles in preclinical research. Finally, we discuss the challenges that have hindered the clinical translation of lipid-based nanoparticles for chemoimmunotherapy, and their future perspectives.

【 授权许可】

Unknown